Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2023, on SEDAR.
Additionally, the company granted 3,700,000 stock options to directors, officers, and consultants, effective March 26, 2024, with an exercise price of $0.07 per share. These options have varying vesting periods and terms, subject to regulatory and TSX Venture Exchange approval.